Evidence map›Paper›PMID 41619008›Full record

ArticleNeuroradiology2026

RECOAT study - Retrospective evaluation of surface-modified and coated flow diverters for the treatment of unruptured intracranial aneurysms.

Lukas Goertz, Sophia Hohenstatt, Dominik F Vollherbst, Charlotte S Weyland, Omid Nikoubashman, Hanna Styczen, Christian Gronemann, Daniel A Weiss, Marius Kaschner, Johannes Rueckel and 14 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lukas GoertzDepartment of Radiology and Neuroradiology, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany. lukas.goertz@uk-koeln.de.
Sophia HohenstattDepartment of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
Dominik F VollherbstDepartment of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
Charlotte S WeylandDepartment of Neuroradiology, University Hospital Aachen, Aachen, Germany.
Omid NikoubashmanDepartment of Neuroradiology, University Hospital Aachen, Aachen, Germany.
Hanna StyczenInstitute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Christian GronemannDepartment of Neuroradiology, University Hospital Bonn, Bonn, Germany.
Daniel A WeissDepartment of Neuroradiology, University Hospital Düsseldorf, Düsseldorf, Germany.
Marius KaschnerDepartment of Neuroradiology, University Hospital Düsseldorf, Düsseldorf, Germany.
Johannes RueckelDepartment of Neuroradiology, University Hospital Munich (LMU), Munich, Germany.
Muriel PflaegingDepartment of Neuroradiology, University Hospital Munich (LMU), Munich, Germany.
Eberhardt SiebertDepartment of Neuroradiology, University Hospital Berlin (Charité), Berlin, Germany.
David ZopfsDepartment of Radiology and Neuroradiology, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.
Jonathan KottlorsDepartment of Radiology and Neuroradiology, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.
Lenhard PennigDepartment of Radiology and Neuroradiology, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.
Marc SchlamannDepartment of Radiology and Neuroradiology, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.
Georg BohnerDepartment of Neuroradiology, University Hospital Berlin (Charité), Berlin, Germany.
Bernd TurowskiDepartment of Neuroradiology, University Hospital Düsseldorf, Düsseldorf, Germany.
Franziska DornDepartment of Neuroradiology, University Hospital Bonn, Bonn, Germany.
Cornelius DeuschlInstitute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
Martin WiesmannDepartment of Neuroradiology, University Hospital Aachen, Aachen, Germany.
Thomas LiebigDepartment of Neuroradiology, University Hospital Munich (LMU), Munich, Germany.
Markus A MöhlenbruchDepartment of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
Christoph KabbaschDepartment of Radiology and Neuroradiology, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSurface modifications may improve procedural safety of flow diverter (FD) treatment, but larger studies are rare. This multicenter study aims to evaluate the safety and efficacy of unruptured aneurysm treatment with surface-modified and coated FDs.

methodsPatients treated with the following FDs at 8 neurovascular centers were retrospectively reviewed: Pipeline Vantage Embolization Device, Pipeline Flex with Shield Technology, FRED X, p48/64 HPC, Derivo Embolization Device (DED), and DED 2heal. Aneurysm characteristics, procedural details, and angiographic results were evaluated in detail.

resultsA total of 511 patients with 545 aneurysms were included (mean aneurysm size: 8.2 ± 5.5 mm, 12% posterior circulation, 14% non-saccular morphology). Multiple FDs were used in 26/515 (5%) procedures and adjunctive coiling in 76 (15%). Thromboembolic events occurred in 40 (7.8%) cases, including 9 (1.7%) major ischemic events, 20 (3.9%) minor ischemic events and 11 (2.1%) asymptomatic/technical events. Non-saccular aneurysm morphology (p = 0.014) and use of multiple FDs (p = 0.025) favored thromboembolic events. Hemorrhagic events occurred in 5 (1.0%) cases, of which 3 were symptomatic. The combined morbidity and mortality rate was 11/515 (2.1%). Complete and adequate occlusion rates were 66% (196/297) and 80% (238/297) at 6 months, respectively, and 70% (64/92) and 85% (78/92) at 12 months, respectively.

conclusionThe present study demonstrates high safety and efficacy for coated or surface-modified FDs. Whether the surface modifications confer a clinical benefit needs to be addressed in comparative studies.

Indexed as

Embolization, TherapeuticIntracranial AneurysmAgedCerebral AngiographyCoated Materials, BiocompatibleFemaleHumansMaleMiddle AgedRetrospective StudiesStentsTreatment OutcomeCoated Materials, BiocompatibleAneurysmAngiographyDeviceFlow diverterIntervention

Identifiers

PMID41619008
PMCPMC13135562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.